For people undergoing cancer treatment, maintaining muscle strength and mass is important for quality of life and treatment tolerance. A new systematic review and meta-analysis suggests that systemic cancer treatments, including chemotherapy and immunotherapy, are linked to a decline in skeletal muscle mass. This finding matters because muscle loss can lead to weakness, fatigue, and poorer outcomes, but the study's limitations mean patients should not panic.
Researchers analyzed 78 studies involving over 10,500 patients with various cancers who were receiving systemic cancer treatment. The studies measured changes in skeletal muscle mass over time, with a median follow-up of about 90 days. The analysis combined the results to estimate the average change in muscle mass during treatment.
The main finding was a small but statistically significant decline in skeletal muscle mass. The standardized mean change was -0.24, which corresponds to about a 5% loss over three months. While this may sound concerning, the effect size is considered small by standard benchmarks. Importantly, the analysis showed substantial variation among studies, meaning the true effect may differ widely depending on the patient, cancer type, and treatment regimen.
Safety outcomes such as adverse events, serious side effects, or treatment discontinuations were not reported in this analysis. The focus was solely on muscle mass changes, so no conclusions can be drawn about other harms or benefits of treatment.
A key caveat is that this is an association, not proof that cancer treatment causes muscle loss. Other factors, such as the cancer itself, reduced physical activity, or poor nutrition, could also contribute. The high heterogeneity (I²=92%) means the pooled estimate is not very reliable, and the authors call for prospective studies with standardized methods to confirm the findings.
For patients, this study does not change current care. Muscle loss during cancer treatment is a known concern, and doctors already monitor nutrition and encourage exercise. The findings reinforce the importance of supportive care but do not suggest that patients should stop or avoid treatment. Anyone worried about muscle loss should talk to their healthcare team about personalized strategies.